Sabina Moldagulova

Sabina Moldagulova


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2024 in Ġylym ža̋ne bìlìm
Verified
Journal Article
Open access
PDF file
САСабира А.
Сабира А.
ЕБЕспембетов Б.
Еспембетов Б.
ЗНЗинина Н.
Зинина Н.
АААбдимухтар А.
Абдимухтар А.
СЕСерікбай Е.б.
Серікбай Е.б.
ШКШораева К.
Шораева К.
В статье приведены результаты комиссионного испытания физико-химических и биологических свойств экспериментальной серии вакцины против бруцеллеза овец и коз из штамма Brucella melitensis Rev-1. При выполнении исследовательских работ использованы бактериологические методы. Наиболее эффективным способом борьбы с бруцеллезом на сегодняшний день считается вакцинация животных. Результаты комиссионных исследовании показали, что вакцина соответствует по своим физико-химическим свойствам всем предъявляемым требованиям и пригодна для специфической профилактики против бруцеллеза овец и коз. Комиссионные испытания физико-химических, биологических свойств конъюнктивальной вакцины изготовленная из штамма Brucella melitensis Rev-1 живой сухой против бруцеллеза овец и коз закончены с положительными результатами и протоколы, акты исследований подписаны членами комиссии ТОО «Научно-исследовательский институт проблем биологической безопасности». На данную вакцину живую сухую конъюнктивальную изготовленного из штамма Brucella melitensis Rev-1, планируется проводить апробационные испытания в условиях Национального референтного центра по ветеринарии Комитета ветеринарного контроля и надзора Министерства сельского хозяйства Республики Казахстан в дальнейшем регистрировать в реестр и получить регистрационных удостоверений на ветеринарные препараты, и применить в овцеводческих хозяйствах.

28 July 2026 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
GNGulnur Nakhanova
Gulnur Nakhanova
OCOlga Chervyakova
Olga Chervyakova
KSKamshat Shorayeva
Kamshat Shorayeva
AZAigerim Zhakypbek
Aigerim Zhakypbek
SMSabina Moldagulova
Sabina Moldagulova
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
Recombinant superoxide dismutase (SOD) protein is a promising antigen candidate for brucellosis vaccines, and its quantitative determination is essential for vaccine quality control, standardization, and regulatory compliance. Although enzyme-linked immunosorbent assay (ELISA) is widely used for antigen quantification, its application to vaccine formulations may be limited due to chemical modifications of antigenic determinants occurring during detoxification and adjuvantation processes. Therefore, alternative analytical methods, such as single radial immunodiffusion (SRID), which enable direct antigen quantification independent of antigenic determinant modifications, represent valuable tools for vaccine analysis. The aim of this study was to develop and validate a single radial immunodiffusion (SRID) assay for the quantitative determination of recombinant SOD protein and to obtain hyperimmune sera in sheep. Sheep were immunized with recombinant SOD protein formulated with aluminum hydroxide or AddaS03 adjuvants. Antibody responses were evaluated using agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). Immunization with aluminum hydroxide induced higher antibody titers than AddaS03. By day 42, ELISA titers reached 1:25,600 in the aluminum hydroxide group compared with 1:3200 in the AddaS03 group. The obtained hyperimmune sera were used for SRID assay development. The optimized SRID assay demonstrated high reproducibility and specificity, with no cross-reactivity against unrelated proteins. A linear relationship was observed between the square of the precipitation ring diameter (D2) and antigen concentration (R2 = 0.956–0.989). The assay showed a limit of detection of 0.312 μg/mL, a linear range of 0.625–10 μg/mL, high precision (CV < 2%), and robustness under varying analytical conditions. The developed SRID assay represents a specific, reproducible, and robust tool for quantitative control of recombinant SOD protein in vaccine formulations.

30 October 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
BYBolat Yespembetov
Bolat Yespembetov
SASabira Alpysbayeva
Sabira Alpysbayeva
MSMakhpal Sarmykova
Makhpal Sarmykova
OCOlga Chervyakova
Olga Chervyakova
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
AAAkbope Abdykalyk
Akbope Abdykalyk
Background/Objectives: Brucellosis remains a widespread zoonosis, yet no licensed human vaccine exists and the live attenuated vaccines used in animals are unsuitable for people because of residual virulence and the risk of accidental infection. Recombinant platforms are attractive alternatives, but direct head-to-head comparisons within a single study are scarce. We compared the safety, immunogenicity and protective efficacy of three recombinant candidates: the AddaS03-adjuvanted subunit vaccine BruVac-Pro, the capripoxvirus-vectored BruVac-CPX and the influenza virus-vectored BruVac-FLU. Methods: Inbred BALB/c mice (n = 355) received a prime-boost immunization, except for the single-dose Rev-1 reference group. A subgroup of 10 animals per group was monitored serologically from day 0 and subsequently challenged intraperitoneally with virulent Brucella melitensis 16M, and the remaining animals were assigned to safety, vector-detection and cellular-immunity read-outs. The timing and prospective nature of allocation to the challenge cohort could not be documented; selection bias in the efficacy endpoint therefore cannot be excluded. Safety was assessed from clinical observation, body weight and early serum clinical chemistry; antigen-specific IgG to Omp16, Omp19, L7/L12 and SodC was measured by indirect ELISA; and protection was quantified from splenic bacterial load (Y), the protective index (PI) and the proportion of animals with no splenic recovery (n = 10 per group). Immunogenicity was assessed as humoral (IgG) responses only; antigen-specific cellular responses were measured in separate subsets of the same experiment and are reported separately. Results: Mortality during the immunization phase was confined to the three sublingually dosed viral-vector and stabilizer groups (CPX/CPX 4/50, CCFLU/CCFLU 3/55, FLU/FLU 1/55), with no deaths in the Pro/Pro, AddaS03/AddaS03, Rev-1 or PBS/PBS groups (8/160 versus 0/195); surviving animals showed no overt clinical signs. Influenza-vector RNA was not detected in serum or spleens at days 3 and 6 by a qualitative assay of undetermined sensitivity. Seroconversion to Omp16 and Omp19 was confined to the Pro-containing group; no animal in any group seroconverted to SodC, and responses to L7/L12 were confined to isolated single animals without a group-level pattern. Splenic burden differed across groups (Kruskal–Wallis, p = 4 × 10−7). BruVac-Pro gave the strongest protection (Y 2.32; PI 2.62; 70.0% with no recovery; p = 0.028 for splenic burden and adjusted p = 0.015 for the proportion of animals with no recovery, both versus the phosphate-buffered saline (PBS) control). BruVac-CPX showed only a non-significant trend towards reduced burden (PI 1.54; p = 0.57 after correction for multiple comparisons) without increasing clearance (20.0%), and BruVac-FLU did not prevent colonization. Rev-1 confirmed model validity (PI 3.15; 80.0%). Conclusions: Under the non-equivalent, formulation-specific regimens tested, BruVac-Pro was the only experimental formulation with no mortality and no overt clinical signs, produced the most consistent antigen-specific IgG response, and was the only experimental candidate to reduce day-14 splenic burden significantly relative to the PBS and adjuvant-only controls. These findings support further dose, mechanism and durability studies of this formulation, but do not establish platform superiority, sterile protection or suitability for human use.